Beth Kirkpatrick
| Beth Kirkpatrick | |
| Occupation | Vaccine researcher |
|---|---|
Beth Kirkpatrick is a vaccine researcher at the University of Vermont, known for her work on dengue vaccine development and on the genetics of infectious diarrheal disease in infants.[1]
Research
Kirkpatrick's published work spans dengue vaccine immunogenicity, poliovirus vaccination, and genome-wide association studies of pediatric diarrheal illness in Bangladesh.[2] According to Semantic Scholar, her body of work totals 122 papers with 6,165 citations and an h-index of 39.[3]
She has contributed to clinical trials of the TV005 tetravalent dengue vaccine, including studies evaluating its safety, immunogenicity, and protective efficacy across dengue serotypes using controlled human infection models.[4][5] Her research also includes genome-wide association studies examining host genetic factors in diarrhea frequency, duration, and Campylobacter infection among infants in Bangladesh.[6][7]
According to National Institutes of Health records, Kirkpatrick has been associated with 54 funded projects at the University of Vermont totaling $46,135,350, including "Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine" ($691,291), an "Administrative Core" award ($1,199,762), and the "Translational Global Infectious Diseases Research Center" ($2,294,927).[8]
Selected publications
- "Targeting hepatitis B vaccine escape using immunogenetics in Bangladeshi infants" (2023), medRxiv[9]
- "Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines" (2023), medRxiv[10]
- "TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies" (2023), Journal of Clinical Investigation[11]
- "Genome-wide association studies of diarrhea frequency and duration in the first year of life in Bangladeshi infants" (2023), Journal of Infectious Diseases[12]
- "Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial" (2023), Lancet Infectious Diseases[13]
- "Maternal Breast Milk Secretor Phenotype Does Not Affect Infant Susceptibility to Rotavirus Diarrhea" (2023), Open Forum Infectious Diseases[14]
- "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial" (2022), Vaccine[15]
- "Genome-Wide Association Study of Campylobacter-Positive Diarrhea Identifies Genes Involved in Toxin Processing and Inflammatory Response" (2022), mBio[16]
- "Evaluating the Safety and Immunogenicity of the rZIKV/D4Δ30-713 Live Attenuated Chimeric Zika Candidate Vaccine in Healthy Flavivirus-Naïve Adults" (2022), Open Forum Infectious Diseases[17]
- "The gut microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants" (2021), medRxiv[18]
External links
- ↑ Semantic Scholar author profile, Beth Kirkpatrick
- ↑ Semantic Scholar author profile, Beth Kirkpatrick
- ↑ Semantic Scholar author profile, Beth Kirkpatrick
- ↑ TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies, Journal of Clinical Investigation, 2023
- ↑ Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial, Lancet Infectious Diseases, 2023
- ↑ Genome-wide association studies of diarrhea frequency and duration in the first year of life in Bangladeshi infants, Journal of Infectious Diseases, 2023
- ↑ Genome-Wide Association Study of Campylobacter-Positive Diarrhea Identifies Genes Involved in Toxin Processing and Inflammatory Response, mBio, 2022
- ↑ National Institutes of Health grant records, University of Vermont & State Agricultural College
- ↑ Targeting hepatitis B vaccine escape using immunogenetics in Bangladeshi infants, medRxiv, 2023
- ↑ Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines, medRxiv, 2023
- ↑ TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies, Journal of Clinical Investigation, 2023
- ↑ Genome-wide association studies of diarrhea frequency and duration in the first year of life in Bangladeshi infants, Journal of Infectious Diseases, 2023
- ↑ Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial, Lancet Infectious Diseases, 2023
- ↑ Maternal Breast Milk Secretor Phenotype Does Not Affect Infant Susceptibility to Rotavirus Diarrhea, Open Forum Infectious Diseases, 2023
- ↑ Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial, Vaccine, 2022
- ↑ Genome-Wide Association Study of Campylobacter-Positive Diarrhea Identifies Genes Involved in Toxin Processing and Inflammatory Response, mBio, 2022
- ↑ Evaluating the Safety and Immunogenicity of the rZIKV/D4Δ30-713 Live Attenuated Chimeric Zika Candidate Vaccine in Healthy Flavivirus-Naïve Adults, Open Forum Infectious Diseases, 2022
- ↑ The gut microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants, medRxiv, 2021